DOCSLIB.ORG

UMDNJ FINAL ANNUAL INSTITUTIONAL PROFILE June 30

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UMDNJ FINAL ANNUAL INSTITUTIONAL PROFILE June 30 UMDNJ FINAL ANNUAL INSTITUTIONAL PROFILE June 30, 2013 University of Medicine and Dentistry of New Jersey Office of Institutional Research – University Office of Academic Affairs UMDNJ–ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 INTRODUCTION This Profile, dated as of June 30, 2013, is the final UMDNJ Annual Institutional Profile. On July 1, 2013, the New Jersey Medical and Health Sciences Education Restructuring Act went into effect, changing the historic configuration of UMDNJ schools and units. Seven of the eight UMDNJ schools became part of a restructured Rutgers University. The UMDNJ- School of Osteopathic Medicine joined with Rowan University, and the University Hospital became a free-standing instrumentality of the State of New Jersey. UMDNJ-ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 TABLE OF CONTENTS ANNUAL INSTITUTIONAL PROFILE June 30, 2013 PAGE DEANS ................................................................................................ 1 PROFILE OF UMDNJ Schools .............................................................................................. 3 Degree and Certificate Programs ...................................................... 6 Dual-Degree Programs ...................................................................... 11 Articulated Programs ......................................................................... 13 Pipeline and Academic Support Programs ........................................ 15 Graduate Medical and Dental Education Programs ........................... 18 Accrediting Agencies ......................................................................... 19 Tuition History. ................................................................................... 21 University Libraries ............................................................................ 22 Center for Continuing and Outreach Education ................................. 25 Centers and Institutes ........................................................................ 28 Major Teaching Facilities ................................................................... 33 University Health Care Facilities ........................................................ 34 Clinical Affiliates ................................................................................. 38 PROFILE OF THE STUDENT BODY Enrollment .......................................................................................... 48 Admissions ........................................................................................ 51 Financial Aid: State, Federal and Institution Funded Programs ......... 63 Degrees and Certificates Awarded .................................................... 64 Graduation Rates ............................................................................... 65 Post-Graduate Placement of Medical and Dental Students ............... 86 Postdoctoral Appointees .................................................................... 88 UMDNJ-ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 TABLE OF CONTENTS cont’d. PAGE PROFILE OF FACULTY, STAFF, INTERNS & RESIDENTS Faculty Paid Faculty AY 2012-13 ........................................................ 89 Master Educators .................................................................... 90 Endowed Chairs ...................................................................... 94 Medical & Dental Interns, Residents and Fellows .............................. 97 Non-Faculty Employees ..................................................................... 104 MEETING THE STATE’S NEEDS Public and Community Service ......................................................... 105 RESEARCH AND EXTERNAL FUNDING FY 2013 Final UMDNJ Research Report, Introduction ............................. 187 Research Facts .................................................................................. 188 Life Sciences Research ..................................................................... 189 Clinical Research ............................................................................... 190 Human Subject Protection Program .................................................. 192 Research Collaborations and Affiliations ........................................... 193 Economic Impact ............................................................................... 194 External Funding Totals for Fiscal Year 2012 ........................ 195 Academic R&D Expenditures for Fiscal Year 2012 ................ 196 Patents and Licenses Patents, Technology Transfer and Business Development ..... 197 Patents Issued July 1 2012 to June 30, 2013 ......................... 199 License and Option Agreements Executed Between July 1, 2012 and June 30, 2013 ....................................... 200 Research Structure ............................................................................ 202 Research Highlights Basic Sciences ........................................................................ 203 Translational Research ........................................................... 231 Clinical Sciences ..................................................................... 236 Educational Research ............................................................. 256 Other Research ....................................................................... 259 UMDNJ-ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 TABLE OF CONTENTS cont’d. PAGE Current Research Projects with Source of Funds Federal Funding ...................................................................... 262 Other Governmental Funding .................................................. 274 Non-Governmental Non-Profit Sponsors................................. 275 Private Industry ....................................................................... 281 Foundation of UMDNJ ............................................................. 285 Internal UMDNJ Funding ......................................................... 287 APPENDIX University Facilities & Capital Planning .............................................. 291 UMDNJ-ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 DEANS Peter S. Amenta, MD, PhD Dean, UMDNJ-Robert Wood Johnson Medical School Thomas A. Cavalieri, DO Dean, UMDNJ-School of Osteopathic Medicine Cecile A. Feldman, DMD, MBA Dean, UMDNJ-New Jersey Dental School Robert L. Johnson, MD Dean, UMDNJ-New Jersey Medical School 1 UMDNJ Annual Institutional Profile, June 30, 2013 DEANS DEANS Julie O’Sullivan Maillet, PhD Interim Dean, UMDNJ-School of Health Related Professions George Rhoads, MD, MPH Interim Dean, UMDNJ-School of Public Health Susan W. Salmond, EdD, RN Dean, UMDNJ-School of Nursing Kathleen W. Scotto, PhD Dean, UMDNJ-Graduate School of Biomedical Sciences 2 PROFILE OF UMDNJ Schools ......................................................................................... 3 Degree and Certificate Programs ................................................. 6 Dual-Degree Programs ................................................................. 11 Articulated Programs .................................................................... 13 Pipeline and Academic Support Programs .................................. 15 Graduate Medical and Dental Education Programs ...................... 18 Accrediting Agencies .................................................................... 19 Tuition History ............................................................................... 21 University Libraries ....................................................................... 22 Continuing Education .................................................................... 25 Centers and Institutes ................................................................... 28 Major Teaching Facilities .............................................................. 33 University Health Care Facilities ................................................... 34 Clinical Affiliates ............................................................................ 38 UMDNJ-ANNUAL INSTITUTIONAL PROFILE, June 30, 2013 SCHOOLS UMDNJ-Graduate School of Biomedical Sciences (GSBS) GSBS at New Jersey Dental School 973-972-3728 185 South Orange Avenue, MSB C-696 Newark, New Jersey 07103 GSBS at New Jersey Medical School 973-972-4511 185 South Orange Avenue, MSB C-696 Newark, New Jersey 07103 GSBS at Robert Wood Johnson Medical School 732-235-5016 675 Hoes Lane, Room R-102 Piscataway, New Jersey 08854-8021 GSBS at School of Osteopathic Medicine 856-566-6282 42 East Laurel Road University Doctors Pavilion Suite 2200 Stratford, New Jersey 08084-1350 UMDNJ-New Jersey Dental School (NJDS) 973-972-4633 110 Bergen Street Post Office Box 1709 Newark, New Jersey 07101-1709 UMDNJ-New Jersey Medical School (NJMS) 973-972-4538 185 South Orange Avenue, MSB C-671 Post Office Box 1709 Newark, New Jersey 07101-1709 3 SCHOOLS UMDNJ-Annual Institutional Profile, June 30, 2013 UMDNJ-Robert Wood Johnson Medical School (RWJMS) 732-235-6300 Piscataway Campus 675 Hoes Lane Piscataway, New Jersey 08854-5635 New Brunswick Campus Clinical Academic Building 125 Paterson Street New Brunswick, New Jersey 08903-0019 Medical Education Building 1 Robert Wood Johnson Place New Brunswick, New Jersey 08903 Camden Campus 401 Haddon Avenue Camden, New Jersey 08103-1506 UMDNJ-School of Health Related Professions (SHRP) 973-972-4276 Newark Campus 65 Bergen Street Suite 120 Newark, New Jersey 07101-1709 Scotch Plains Campus 1776 Raritan Road Scotch Plains, New Jersey 07076-2997 Stratford Campus University Educational Center
Load more

Recommended publications
  • Toxicology Mechanisms Underlying the Neurotoxicity Induced by Glyphosate-Based Herbicide in Immature Rat Hippocampus
    Toxicology 320 (2014) 34–45 Contents lists available at ScienceDirect Toxicology j ournal homepage: www.elsevier.com/locate/toxicol Mechanisms underlying the neurotoxicity induced by glyphosate-based herbicide in immature rat hippocampus: Involvement of glutamate excitotoxicity Daiane Cattani, Vera Lúcia de Liz Oliveira Cavalli, Carla Elise Heinz Rieg, Juliana Tonietto Domingues, Tharine Dal-Cim, Carla Inês Tasca, ∗ Fátima Regina Mena Barreto Silva, Ariane Zamoner Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil a r a t i b s c l t r e a i n f o c t Article history: Previous studies demonstrate that glyphosate exposure is associated with oxidative damage and neu- Received 23 August 2013 rotoxicity. Therefore, the mechanism of glyphosate-induced neurotoxic effects needs to be determined. Received in revised form 12 February 2014 ® The aim of this study was to investigate whether Roundup (a glyphosate-based herbicide) leads to Accepted 6 March 2014 neurotoxicity in hippocampus of immature rats following acute (30 min) and chronic (pregnancy and Available online 15 March 2014 lactation) pesticide exposure. Maternal exposure to pesticide was undertaken by treating dams orally ® with 1% Roundup (0.38% glyphosate) during pregnancy and lactation (till 15-day-old). Hippocampal Keywords: ® slices from 15 day old rats were acutely exposed to Roundup (0.00005–0.1%) during 30 min and experi- Glyphosate 45 2+ Calcium ments were carried out to determine whether glyphosate affects Ca influx and cell viability. Moreover, 14 we investigated the pesticide effects on oxidative stress parameters, C-␣-methyl-amino-isobutyric acid Glutamatergic excitotoxicity 14 Oxidative stress ( C-MeAIB) accumulation, as well as glutamate uptake, release and metabolism.
    [Show full text]
  • Crews Lab Discovers Inflammatory Mechanisms Underlying Alcohol
    research alcohol actions on brain, liver, pancreas, fetus, the The Director’s Column endocrine system and the immune system, has contributed Thanks for your gifts to our Center! to Crews’ insights. Alternatively, I suspect that he A. Leslie Morrow, Ph.D. assembled this diverse group of researchers to study alcohol Dean’’’ s Club Ms. Carolyn S. Corn Mr. and Mrs. Ben Madore Associate Director, actions across so many systems of the body for the very Ms. Harriet W. Crisp Bowles Center for (annual gifts of $5000 and above) Ms. Regina J. Mahon purpose of discovering how the complex systemic and Mr. and Mrs. Ray Damerell Alcohol Studies Dr. William Maixner molecular roles of alcohol go awry in the disease of Center Line James A. Bowles Mr. Lewis A. Dancy Mrs. Melissa M. Mann Bowles Center for Alcohol Studies alcoholism. Mr. John N. Howard, Jr. Mr. F. E. Danielus Mr. and Mrs. H. J. McCarthy School of Medicine, University of North Carolina at Chapel Hill Mr. and Mrs. Robert F. Schaecher Mr. Stephen M. Dean and Ms. Patricia L. Ms. Michelle McCarthy This integration of research across systems, organs, brain Ms. Ann Lewallen Spencer Amend Mr. and Mrs. Robert H. McConville, Jr. Dr. Fulton Crews’ brilliance can be attributed in part to regions, human development and the progression to Our mission is to conduct, coordinate, and promote basic and clinical research on the causes, prevention, and treatment of alcoholism and alcoholic disease. Tennessee Medical Foundation Ms. Elizabeth L. Deaver Mr. and Mrs. Loyce L. McCormick his understanding that human beings are not just a alcoholism is the hallmark of research in the Bowles Center Ms.
    [Show full text]
  • Assessing Neurotoxicity of Drugs of Abuse
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Assessing Neurotoxicity of Drugs of Abuse 136 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Assessing Neurotoxicity of Drugs of Abuse Editor: Lynda Erinoff, Ph.D. NIDA Research Monograph 136 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Assessing Neurotoxicity of Drugs of Abuse” held on May 20-21, 1991, in Bethesda, MD. The technical review was sponsored by the National Institute on Drug Abuse (NIDA). COPYRIGHT STATUS NIDA has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • The Neurotoxin Β-N-Methylamino-L-Alanine (BMAA)
    The neurotoxin β-N-methylamino-L-alanine (BMAA) Sources, bioaccumulation and extraction procedures Sandra Ferreira Lage ©Sandra Ferreira Lage, Stockholm University 2016 Cover image: Cyanobacteria, diatoms and dinoflagellates microscopic pictures taken by Sandra Ferreira Lage ISBN 978-91-7649-455-4 Printed in Sweden by Holmbergs, Malmö 2016 Distributor: Department of Ecology, Environment and Plant Sciences, Stockholm University “Sinto mais longe o passado, sinto a saudade mais perto.” Fernando Pessoa, 1914. Abstract β-methylamino-L-alanine (BMAA) is a neurotoxin linked to neurodegeneration, which is manifested in the devastating human diseases amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease. This neurotoxin is known to be produced by almost all tested species within the cyanobacterial phylum including free living as well as the symbiotic strains. The global distribution of the BMAA producers ranges from a terrestrial ecosystem on the Island of Guam in the Pacific Ocean to an aquatic ecosystem in Northern Europe, the Baltic Sea, where annually massive surface blooms occur. BMAA had been shown to accumulate in the Baltic Sea food web, with highest levels in the bottom dwelling fish-species as well as in mollusks. One of the aims of this thesis was to test the bottom-dwelling bioaccumulation hy- pothesis by using a larger number of samples allowing a statistical evaluation. Hence, a large set of fish individuals from the lake Finjasjön, were caught and the BMAA concentrations in different tissues were related to the season of catching, fish gender, total weight and species. The results reveal that fish total weight and fish species were positively correlated with BMAA concentration in the fish brain.
    [Show full text]
  • Co-Occurrence of the Cyanotoxins BMAA, DABA and Anatoxin-A in Nebraska Reservoirs, Fish, and Aquatic Plants
    Toxins 2014, 6, 488-508; doi:10.3390/toxins6020488 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Article Co-occurrence of the Cyanotoxins BMAA, DABA and Anatoxin-a in Nebraska Reservoirs, Fish, and Aquatic Plants Maitham Ahmed Al-Sammak 1,3, Kyle D. Hoagland 2, David Cassada 3 and Daniel D. Snow 3,* 1 Environmental Health, Occupational Health, & Toxicology, Tropical Biological Researches Unit, College of Science, University of Baghdad, Baghdad 10071, Iraq; E-Mail: [email protected] 2 School of Natural Resources, University of Nebraska, Lincoln, NE 68583, USA; E-Mail: [email protected] 3 Nebraska Water Center and School of Natural Resources, University of Nebraska-Lincoln, Lincoln, NE 68583, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed: E-Mail: [email protected]; Tel.: +1-402-472-7539; Fax: +1-402-472-9599. Received: 12 November 2013; in revised form: 19 December 2013 / Accepted: 17 January 2014 / Published: 28 January 2014 Abstract: Several groups of microorganisms are capable of producing toxins in aquatic environments. Cyanobacteria are prevalent blue green algae in freshwater systems, and many species produce cyanotoxins which include a variety of chemical irritants, hepatotoxins and neurotoxins. Production and occurrence of potent neurotoxic cyanotoxins β-N-methylamino-L-alanine (BMAA), 2,4-diaminobutyric acid dihydrochloride (DABA), and anatoxin-a are especially critical with environmental implications to public and animal health. Biomagnification, though not well understood in aquatic systems, is potentially relevant to both human and animal health effects. Because little is known regarding their presence in fresh water, we investigated the occurrence and potential for bioaccumulation of cyanotoxins in several Nebraska reservoirs.
    [Show full text]
  • Widespread and Differential Neurotoxicity In
    Neurotoxicity Research https://doi.org/10.1007/s12640-021-00330-4 ORIGINAL ARTICLE Widespread and Diferential Neurotoxicity in Venoms from the Bitis Genus of Viperid Snakes Nicholas J. Youngman1 · Richard J. Harris1 · Tam M. Huynh2 · Kristian Coster3 · Eric Sundman3 · Ralph Braun4 · Arno Naude5 · Wayne C. Hodgson2 · Bryan G. Fry1 Received: 24 November 2020 / Revised: 2 January 2021 / Accepted: 5 January 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 Abstract Research into the neurotoxic activity of venoms from species within the snake family Viperidae is relatively neglected com- pared with snakes in the Elapidae family. Previous studies into venoms from the Bitis genus of vipers have identifed the pres- ence of presynaptic phospholipase A2 neurotoxins in B. atropos and B. caudalis, as well as a postsynaptic phospholipase A2 in B. arietans. Yet, no studies have investigated how widespread neurotoxicity is across the Bitis genus or if they exhibit prey selectivity of their neurotoxins. Utilising a biolayer interferometry assay, we were able to assess the binding of crude venom from 14 species of Bitis to the neuromuscular α-1 nAChR orthosteric site across a wide range of vertebrate taxa mimotopes. Postsynaptic binding was seen for venoms from B. arietans, B. armata, B. atropos, B. caudalis, B. cornuta, B. peringueyi and B. rubida. To further explore the types of neurotoxins present, venoms from the representatives B. armata, B. caudalis, B. cornuta and B. rubida were additionally tested in the chick biventer cervicis nerve muscle preparation, which showed presynaptic and postsynaptic activity for B.
    [Show full text]
  • Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats
    The Journal of Neuroscience, October 1988, B(10): 3901-3908 Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats M. Flint Beal, Neil W. Kowall, Kenton J. Swartz, Robert J. Ferrante, and Joseph B. Martin Neurology Service, Massachusetts General Hospital, and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02114 Quinolinic acid (QA) is an endogenous excitotoxin present mammalian brain, is an excitotoxin which producesaxon-spar- in mammalian brain that reproduces many of the histologic ing striatal lesions. We found that this compound produced a and neurochemical features of Huntington’s disease (HD). more exact model of HD than kainic acid, sincethe lesionswere In the present study we have examined the ability of a variety accompaniedby a relative sparingof somatostatin-neuropeptide of systemically administered compounds to modify striatal Y neurons (Beal et al., 1986a). QA neurotoxicity. Lesions were assessed by measurements If an excitotoxin is involved in the pathogenesisof HD, then of the intrinsic striatal neurotransmitters substance P, so- agentsthat modify excitotoxin lesionsin vivo could potentially matostatin, neuropeptide Y, and GABA. Histologic exami- be efficacious as therapeutic agents in HD. The best form of nation was performed with Nissl stains. The antioxidants therapy from a practical standpoint would be a drug that could ascorbic acid, beta-carotene, and alpha-tocopherol admin- be administered systemically, preferably by an oral route. In the istered S.C. for 3 d prior to striatal QA lesions had no sig- presentstudy we have therefore examined the ability of a variety nificant effect. Other drugs were administered i.p. l/2 hr prior of systemically administered drugs to modify QA striatal neu- to QA striatal lesions.
    [Show full text]
  • Fluorine-18-FPH for PET Imaging of Nicotinic Acetylcholine Receptors
    32. Holman BL. Hcllman RS. Goldsmith SJ, et al. Biodislribution. dosimetry. and clinical 34. Suess E, Huck S, Reither H, Hortnagl H, Angelberger P. Uptake mechanism of evaluation of technetium-99m-ethyl cystcinate dimer in normal subjects and in patients technetium-99m-d. I-HMPAO in cell cultures of the dissociated postnatal rat cerebel with chronic cerebral infarction. J NucíMed 1989:30:1018-1024. lum. J NucíMed 1992:33:108-114. 33. Andersen AR. Technetium-99m-HMPAO: basic kinetic studies of a tracer of cerebral 35. Moretti JL, Caglar M, Weinmann P. Cerebral perfusion imaging tracers for SPECT: blood flow. Cerehrovasc Brain Metab Rev 1989:1:288-318. which one to choose? J NucíMed 1995:36:359-363. Fluorine-18-FPH for PET Imaging of Nicotinic Acetylcholine Receptors Andrew Horti, Ursula Scheffel, Marigo Stathis, Paige Finley, Hayden T. Ravert, Edythe D. London and Robert F. Dannais Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland; and Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins Medical School, Baltimore, Maryland studied extensively. Molecular biological techniques have been Visualization of central nicotinic acetylcholine receptors (nAChRs) applied in determining the amino acid sequences of the subunits with modern PET or SPECT imaging techniques has been ham that compose the receptor (1-3), autoradiographic techniques pered by the lack of a radioligand with suitable in vivo binding characteristics (i.e., high target-to-nontarget ratios and kinetics have been used to delineate the anatomical distribution of appropriate for the half-life of the tracer and imaging modality used). nAChRs in brain (4-7} and metabolic mapping studies have This paper describes in vivo binding, kinetics and pharmacology of demonstrated that the specific binding sites labeled in brain a highly potent 18F-labeled analog of epibatidine, (±)-exo-2-(2- with specific radioligands are coupled to functional activity (8).
    [Show full text]
  • 1 3,4-Methylenedioxy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Diposit Digital de la Universitat de Barcelona 3,4-Methylenedioxy-methamphetamine induces in vivo regional up- regulation of central nicotinic receptors in rats and potentiates the regulatory effects of nicotine on these receptors Authors: David Pubill, Sara Garcia-Ratés, Jordi Camarasa, Elena Escubedo Address: Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia, Nucli Universitari de Pedralbes, Universitat de Barcelona, Institut de Biomedicina de la UB (IBUB), 08028 Barcelona, Spain Email: D. Pubill: [email protected] S. Garcia: [email protected] J. Camarasa: [email protected] E. Escubedo: [email protected] Corresponding author: Name: David Pubill Address: Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia, Av. Joan XXIII s/n; 08028 Barcelona, SPAIN Tel: (+34) 934024531 Fax: (+34) 934035982 Email: [email protected] 1 Abstract Nicotine (NIC), the main psychostimulant compound of smoked tobacco, exerts its effects through activation of central nicotinic acetylcholine receptors (nAChR), which become up-regulated after chronic administration. Recent work has demonstrated that the recreational drug 3,4-methylenedioxy- methamphetamine (MDMA) has affinity for nAChR and also induces up- regulation of nAChR in PC 12 cells. Tobacco and MDMA are often consumed together. In the present work we studied the in vivo effect of a classic chronic dosing schedule of MDMA in rats, alone or combined with a chronic schedule of NIC, on the density of nAChR and on serotonin reuptake transporters. MDMA induced significant decreases in [3H]paroxetine binding in the cortex and hippocampus measured 24 h after the last dose and these decreases were not modified by the association with NIC.
    [Show full text]
  • Running Head: CYANOBACTERIA, Β-METHYLAMINO-L-ALANINE
    Running head: CYANOBACTERIA, b-METHYLAMINO-L-ALANINE, AND NEURODEGENERATION Cyanobacteria, β-Methylamino-L-Alanine, and Neurodegeneration Jonathan Hunyadi Lourdes University CYANOBACTERIA, b-METHYLAMINO-L-ALANINE, AND NEURODEGENERATION 2 ABSTRACT Research has found a potential link between the non-proteinogenic amino acid b-methylamino-L-alanine (BMAA) and neurodegenerative diseases. First identified on the island of Guam with a rare form of amyotrophic lateral sclerosis (ALS) commonly called “Guam disease”, the source of BMAA was identified to be cyanobacteria. Due primarily to eutrophication, cyanobacteria can form large “algal blooms” within water bodies. A major concern during cyanobacterial blooms is the production of high concentrations of cyanotoxins such as BMAA. Cyanotoxin biosynthesis is dependent on the presence of specific genes as well as environmental regulating factors. Numerous techniques are capable of analyzing cyanobacteria and cyanotoxins which include: microscopy, pigment spectroscopy, polymerase chain reaction, microarrays, enzyme-linked immunosorbent assays, and liquid chromatography. Liquid chromatography is the primary technique used to analyze BMAA, however, there has been controversy regarding its detection within nervous tissue samples. While BMAAs role in neurodegeneration is unclear, dietary intake has been demonstrated to produce both b-amyloid plaques and tau tangles within Vervet monkeys, hallmarks of both Alzheimer’s disease and Guam disease. Two of the dominant hypothesized mechanisms of BMAA neurotoxicity are glutamate excitotoxicity, by which BMAA functions as a glutamate agonist causing endoplasmic reticulum stress and initiates a cascade leading to tau hyperphosphorylation, and protein incorporation, by which BMAA enters neurons and becomes mis-incorporated within proteins, leading to misfolding and aggregation. As a result of this research, alanine supplements have entered clinical trials for both Alzheimer’s disease and ALS to compete with BMAA in protein incorporation.
    [Show full text]
  • Toxins from Cyanobacteria
    FRI FOOD SAFETY REVIEWS TOXINS FROM CYANOBACTERIA M. Ellin Doyle Food Research Institute University of Wisconsin–Madison Madison WI 53706 Contents34B Microcystins...................................................................................................................................2 Beta-methylamino-L-alanine (BMAA)..........................................................................................3 Paralytic Shellfish Poisoning (PSP) Toxins ...................................................................................3 Anatoxin-a .....................................................................................................................................3 References......................................................................................................................................4 Appendix — FRI Briefing, May 1998: Toxins from Algae/Cyanobacteria (includes Pfiesteria) Cyanobacteria (previously called blue green algae) are strain-specific and is influenced by environmental ancient single-celled organisms, widely distributed in factors. These toxins include: aquatic environments, soil, and other moist surfaces Microcystins: heat stable, cyclic heptapep- and can survive in very inhospitable environments such tides that are toxic to liver cells and promote as hot springs and the arctic tundra. Some species growth of some tumors partner with fungi to form lichens, and others engage Beta-methylamino-L-alanine (BMAA): in symbiotic relationships with higher plants. Cyano- a neurotoxin, possibly
    [Show full text]
  • Proposed Nationa Strategy for the Prevention of Neurotoxic Disorders
    Proposed Nationa Strategy for the Prevention of Neurotoxic Disorders U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control National Institute for Occupational Safety and Health 1988 ~~~~(~10S~)~ublicationNo. 89-134 introduction This document, A Proposed Natiimul Strategg for the Prmention of Neurotoxic Disorders, sum- marizes what actions need to be taken to prevent occupational neurotoxic disorders. It was developed in 1985 at a conference sponsored by the National Institute for Occupational Safety and Health (NIOSH) and The Association of Schools of Public Health (ASPH), which brought together over 50 expert panelists and 450 other occupational safety and health professionals. In addition to the strategy for neurotoxic disorders, NIOSH and ASPH have published strategies for the other nine leading occupational diseases and injuries: occupational lung diseases, mus- culoskeletal injuries, occupational cancers, severe occupational traumatic injuries, occupational cardiovascular diseases, disorders of reproduction, noise-induced hearing loss, dermatological conditions and psychological disorders. The proposed strategies were originally published in a two volume set, Proposed NaCional Strat- egiesfor the Preuentzbn of Leading Work-RelatedDiseases and Injuries, Part 1 and Part 2. These proposed strategies are not to be considered as final statements of policy of NIOSH, The Association of Schools of Public Health, or of any agency or individual who was involved. Hopefully, they will be used in the quest to prevent disease and injury in the workplace. To learn of the availability of the complete texts of Part 1and Part 2, or to obtain additional copies of this or other Strategies, contact NIOSH Publications, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
    [Show full text]